

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LIN ET AL.

Art Unit: 4173

APPLICATION NO: 10/530,857

Examiner: Benjamin Packard

FILED: APRIL 8, 2005

FOR: EPOTHILONE DERIVATIVES FOR THE TREATMENT OF
MULTIPLE MYELOMA

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,


George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824
Date: July 24, 2008

CASE ON/4-32633A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
LIN ET AL.

INTERNATIONAL APPLICATION NO: PCT/IB03/04480

Art Unit: 4173

FILED: 10 OCTOBER 2003

Examiner: Benjamin Packard

U.S. APPLICATION NO: 10/530,857

35 USC §371 DATE: 8 APRIL 2005

FOR: EPOTHILONE DERIVATIVES FOR THE TREATMENT OF
MULTIPLE MYELOMA

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/IB03/04480, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "George R. Dohmann", written over a horizontal line.

George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: July 24, 2008